Nuvectis gains two experimental drugs in licensing deal with China's Haisco

Nuvectis Pharma licensed exclusive rights outside China to two experimental drugs from Haisco Pharmaceutical Group, expanding its pipeline in complement-mediated diseases and cancer. The deal broadens the company's development portfolio and could add strategic optionality, though the article provides no financial terms. The announcement is positive for pipeline breadth but is unlikely to be a major near-term market mover.

Analysis

Nuvectis Pharma licensed exclusive rights outside China to two experimental drugs from Haisco Pharmaceutical Group, expanding its pipeline in complement-mediated diseases and cancer. The deal broadens the company's development portfolio and could add strategic optionality, though the article provides no financial terms. The announcement is positive for pipeline breadth but is unlikely to be a major near-term market mover.